Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: April 9, 2010
Last updated: January 20, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)